US6355681B2
(en)
*
|
1995-12-07 |
2002-03-12 |
Glytech, Inc. |
Glycine substitutes and precursors for treating a psychosis
|
US6512010B1
(en)
*
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
ES2164040T3
(es)
|
1998-04-14 |
2008-02-01 |
The General Hospital Corporation |
Uso de d-serina o de d-alanina para el tratamiento de la esquizofrenia.
|
HUP0103781A3
(en)
*
|
1998-10-16 |
2003-09-29 |
Janssen Pharmaceutica Nv |
Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
DE19918105C1
(de)
*
|
1999-04-22 |
2000-09-21 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
|
US7146209B2
(en)
*
|
2000-05-08 |
2006-12-05 |
Brainsgate, Ltd. |
Stimulation for treating eye pathologies
|
EP1365787B1
(en)
|
2000-08-25 |
2007-03-21 |
Research Corporation Technologies, Inc |
Use of amino acid anticonvulsants for treatment of pain
|
US20070117869A1
(en)
*
|
2000-11-01 |
2007-05-24 |
Cognition Pharmaceuticals Llc |
Methods for treating coginitive impairment and improving cognition
|
US7619005B2
(en)
*
|
2000-11-01 |
2009-11-17 |
Cognition Pharmaceuticals Llc |
Methods for treating cognitive impairment in humans with Multiple Sclerosis
|
US20030232890A1
(en)
*
|
2000-11-01 |
2003-12-18 |
Sention, Inc. |
Methods for treating an impairment in memory consolidation
|
US20030119884A1
(en)
*
|
2000-11-01 |
2003-06-26 |
Epstein Mel H. |
Methods and compositions for regulating memory consolidation
|
US20050059743A1
(en)
*
|
2000-11-01 |
2005-03-17 |
Sention, Inc. |
Methods for treating mild cognitive impairment and alzheimer's disease
|
AU2002239464B2
(en)
*
|
2000-11-01 |
2007-01-04 |
Cognition Pharmaceuticals Llc |
Methods and compositions for regulating memory consolidation
|
US20020155170A1
(en)
*
|
2000-11-30 |
2002-10-24 |
Walsh William John |
Nutrient supplements and methods for treating autism and for preventing the onset of autism
|
US20030185754A1
(en)
*
|
2001-01-16 |
2003-10-02 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
US20030166554A1
(en)
*
|
2001-01-16 |
2003-09-04 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
ATE519485T1
(de)
*
|
2001-03-29 |
2011-08-15 |
Michael Davis |
Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
|
WO2005016319A2
(en)
*
|
2003-08-06 |
2005-02-24 |
Emory University |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
EP1935414A3
(en)
*
|
2001-05-02 |
2010-08-18 |
Blanchette Rockefeller Neurosciences Institute |
Carbonic anhydrase activators for enhancig learning and memory
|
CA2744115A1
(en)
*
|
2001-05-02 |
2002-11-07 |
Blanchette Rockefeller Neurosciences Institute |
Carbonic anhydrase activators for enhancing learning and memory
|
US7645442B2
(en)
|
2001-05-24 |
2010-01-12 |
Alexza Pharmaceuticals, Inc. |
Rapid-heating drug delivery article and method of use
|
US20030051728A1
(en)
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
US7498019B2
(en)
|
2001-05-24 |
2009-03-03 |
Alexza Pharmaceuticals, Inc. |
Delivery of compounds for the treatment of headache through an inhalation route
|
CA2446904A1
(en)
|
2001-05-24 |
2003-04-03 |
Alexza Molecular Delivery Corporation |
Delivery of drug esters through an inhalation route
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
US7005138B2
(en)
*
|
2001-12-21 |
2006-02-28 |
Duramed Pharmaceuticals, Inc. |
Method of systematically delivering SSRIs
|
CA2470496A1
(en)
|
2001-12-28 |
2003-07-17 |
Teva Pharmaceutical Industries Ltd. |
A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
|
BE1015608A6
(fr)
*
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
JPWO2003068215A1
(ja)
*
|
2002-02-14 |
2005-06-02 |
味の素株式会社 |
ミトコンドリア病用薬剤
|
US20050176826A1
(en)
*
|
2002-03-15 |
2005-08-11 |
H. Lundbeck A/S |
Use of asc-1 inhibitors to treat neurological and psychiatric disorders
|
US7684859B2
(en)
*
|
2002-04-25 |
2010-03-23 |
Brainsgate Ltd. |
Stimulation of the OTIC ganglion for treating medical conditions
|
WO2004043218A2
(en)
*
|
2002-11-14 |
2004-05-27 |
Brainsgate Ltd. |
Surgical tools and techniques for stimulation
|
JP2005531305A
(ja)
*
|
2002-06-10 |
2005-10-20 |
エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ステロイド産生急性調節タンパク質の神経変性疾患に関する診断的および治療的使用
|
KR100446503B1
(ko)
*
|
2002-06-19 |
2004-09-04 |
삼성전자주식회사 |
복합 억세스 포인트 장치 및 복합 억세스 포인트 장치를이용한 음성/데이터 패킷 처리 방법
|
JP4299243B2
(ja)
*
|
2002-07-04 |
2009-07-22 |
田辺三菱製薬株式会社 |
統合失調症の検査、診断方法
|
AU2003268026A1
(en)
*
|
2002-07-30 |
2004-02-16 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
FR2843590B1
(fr)
*
|
2002-08-14 |
2007-10-05 |
Prestwick Scient Capital Inc |
Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
|
EP2295061A1
(en)
|
2002-08-22 |
2011-03-16 |
Dainippon Sumitomo Pharma Co., Ltd. |
Agent for treatment of schizophrenia
|
US7160913B2
(en)
|
2002-09-13 |
2007-01-09 |
Thomas Jefferson University |
Methods and kit for treating Parkinson's disease
|
US20040067986A1
(en)
*
|
2002-10-04 |
2004-04-08 |
Nathan Sassover |
Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
|
TWI319713B
(en)
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
MXPA05002561A
(es)
*
|
2002-10-25 |
2005-05-05 |
Pfizer Prod Inc |
Nuevas formulaciones de liberacion prolongada inyectables.
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
US20040105818A1
(en)
|
2002-11-26 |
2004-06-03 |
Alexza Molecular Delivery Corporation |
Diuretic aerosols and methods of making and using them
|
US7913688B2
(en)
|
2002-11-27 |
2011-03-29 |
Alexza Pharmaceuticals, Inc. |
Inhalation device for producing a drug aerosol
|
RU2356554C2
(ru)
|
2002-12-27 |
2009-05-27 |
Оцука Фармасьютикал Ко., Лтд. |
Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
|
AR042806A1
(es)
*
|
2002-12-27 |
2005-07-06 |
Otsuka Pharma Co Ltd |
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
|
US20070249537A1
(en)
*
|
2003-01-23 |
2007-10-25 |
Supernus Pharmaceuticals, Inc. |
Absorption enhancing agents
|
IL154318A
(en)
|
2003-02-06 |
2010-05-31 |
Sarah Herzog Memorial Hospital |
Pharmaceutical compositions for the treatment of movement disorders
|
WO2004091601A1
(fr)
*
|
2003-04-17 |
2004-10-28 |
Jallal Messadek |
Formulations orales flottantes pour la liberation controlee de la betaine
|
EP1633360A1
(en)
*
|
2003-05-16 |
2006-03-15 |
Pfizer Products Incorporated |
Treatment of psychotic and depressive disorders
|
EP1625335A2
(en)
|
2003-05-21 |
2006-02-15 |
Alexza Pharmaceuticals, Inc. |
Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
|
WO2004112700A2
(en)
*
|
2003-06-06 |
2004-12-29 |
The General Hospital Corporation |
Methods and compositions for modulating amyloid precursor protein translation
|
WO2004113333A1
(ja)
|
2003-06-23 |
2004-12-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
老人性痴呆症治療剤
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
US7838029B1
(en)
*
|
2003-07-31 |
2010-11-23 |
Watson Laboratories, Inc. |
Mirtazapine solid dosage forms
|
US20060128657A1
(en)
*
|
2003-08-04 |
2006-06-15 |
Jallal Messadek |
Selected betaines and their uses
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
WO2005053703A1
(en)
*
|
2003-12-02 |
2005-06-16 |
Leslie James Sheldon |
Combination therapy for dementia, depression and apathy
|
CA2550650A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Darpharma, Inc. |
Co-administration of dopamine-receptor binding compounds
|
US20120225916A1
(en)
*
|
2003-12-29 |
2012-09-06 |
Mcdevitt Jason P |
Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
|
WO2005065308A2
(en)
*
|
2003-12-29 |
2005-07-21 |
Jason Mcdevitt |
Compositions and methods to treat recurrent medical conditions
|
US20050171088A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Astrazeneca Ab |
Treatment of psychoses with dibenzothiazepine antipsychotic
|
EP2357474A1
(en)
|
2004-02-20 |
2011-08-17 |
Dainippon Sumitomo Pharma Co., Ltd. |
Lurasidone for use in the treatment of memory or learning dysfunction by schizophrenia
|
US9233245B2
(en)
|
2004-02-20 |
2016-01-12 |
Brainsgate Ltd. |
SPG stimulation
|
US8010189B2
(en)
*
|
2004-02-20 |
2011-08-30 |
Brainsgate Ltd. |
SPG stimulation for treating complications of subarachnoid hemorrhage
|
US8055347B2
(en)
|
2005-08-19 |
2011-11-08 |
Brainsgate Ltd. |
Stimulation for treating brain events and other conditions
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
EP1735057B1
(en)
*
|
2004-03-22 |
2015-02-25 |
Apkarian Technologies LLC |
Method and compositions for treatment of chronic neuropathic pain
|
TW201207390A
(en)
|
2004-05-18 |
2012-02-16 |
Brni Neurosciences Inst |
Method for screening agent for antidepressant activity
|
US20050261278A1
(en)
*
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
WO2005115471A2
(en)
*
|
2004-05-27 |
2005-12-08 |
Neurocure Ltd. |
Methods and compositions for treatment of nicotine dependence and dementias
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
EP1604656A1
(en)
|
2004-06-09 |
2005-12-14 |
Schwarz Pharma Ag |
Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
|
CA2601716C
(en)
*
|
2004-06-25 |
2011-05-31 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
WO2006023703A2
(en)
*
|
2004-08-20 |
2006-03-02 |
Cypress Bioscience, Inc. |
Method for treating sleep related breathing disorders
|
US20090299418A1
(en)
*
|
2004-08-23 |
2009-12-03 |
Brainsgate Ltd. |
Concurrent bilateral spg modulation
|
US20060063707A1
(en)
*
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
WO2006050581A2
(en)
*
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
WO2006055854A2
(en)
*
|
2004-11-17 |
2006-05-26 |
Cypress Bioscience, Inc. |
Methods for reducing the side effects associated with mirtazapine treatment
|
WO2006060186A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of dementia and related disorders
|
PL1830833T3
(pl)
*
|
2004-12-16 |
2010-06-30 |
Janssen Pharmaceutica Nv |
Połączenie inhibitora transportera glicyny (GLYT1) i środka przeciwpsychotycznego do leczenia objawów schizofrenii jak również sposoby jego wytwarzania oraz zastosowanie
|
WO2006067529A1
(en)
*
|
2004-12-21 |
2006-06-29 |
Merck Sharp & Dohme Limited |
Piperidine and azetidine derivatives as glyt1 inhibitors
|
WO2006134341A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Merck Sharp & Dohme Limited |
Therapeutic agents
|
CA2615147A1
(en)
*
|
2005-07-14 |
2007-01-18 |
The University Of British Columbia |
Neuroprotective modulation of nmda receptor subtype activities
|
JP2009507047A
(ja)
*
|
2005-09-09 |
2009-02-19 |
ラボファーム インコーポレイテッド |
持続性薬物放出組成物
|
EP1942733B1
(en)
|
2005-09-29 |
2012-03-21 |
Merck Sharp & Dohme Corp. |
Radiolabeled glycine transporter inhibitors
|
CL2007000773A1
(es)
*
|
2006-03-24 |
2008-01-25 |
Wyeth Corp |
Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
|
US7884124B2
(en)
|
2006-06-30 |
2011-02-08 |
Sepracor Inc. |
Fluoro-substituted inhibitors of D-amino acid oxidase
|
TW200820963A
(en)
*
|
2006-07-28 |
2008-05-16 |
Xenoport Inc |
Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
|
US20090210026A1
(en)
*
|
2006-08-17 |
2009-08-20 |
Brainsgate Ltd. |
Spg stimulation for enhancing neurogenesis and brain metabolism
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
US20100129805A1
(en)
*
|
2006-11-09 |
2010-05-27 |
Wai Lun Alan Fung |
Slc1a1 antipsychotic drug response markers
|
WO2008112661A2
(en)
|
2007-03-09 |
2008-09-18 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
WO2008118785A2
(en)
*
|
2007-03-23 |
2008-10-02 |
Tikvah Therapeutics |
Methods for treating depression using immediate-impact treatments and d-cycloserine
|
WO2008124814A2
(en)
*
|
2007-04-10 |
2008-10-16 |
Mcdevitt Jason P |
Sublingual formulations of d-cycloserine and methods of using same
|
US8198305B2
(en)
*
|
2007-04-13 |
2012-06-12 |
Concert Pharmaceuticals Inc. |
1,2-benzisoxazol-3-yl compounds
|
WO2008157094A1
(en)
*
|
2007-06-13 |
2008-12-24 |
Cypress Bioscience, Inc. |
Improving the tolerability of mirtazapine and a second active by using them in combination
|
US8580776B2
(en)
*
|
2007-07-10 |
2013-11-12 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods for treating neurodegenerating diseases
|
WO2009018368A1
(en)
*
|
2007-07-30 |
2009-02-05 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
|
US7860569B2
(en)
|
2007-10-18 |
2010-12-28 |
Brainsgate, Ltd. |
Long-term SPG stimulation therapy for prevention of vascular dementia
|
WO2009065193A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Jallal Messadek |
Treatment of aspirin resistance with betaine and/or betaine enriched molasses
|
IL188681A0
(en)
*
|
2008-01-09 |
2008-12-29 |
Amino Acid Solutions Inc |
Pharmaceutical compositions and methods utilizing a d-amino acid
|
EP2111858A1
(en)
*
|
2008-04-25 |
2009-10-28 |
EPFL Ecole Polytechnique Fédérale de Lausanne |
Novel treatment for alzheimer's disease
|
GB0817379D0
(en)
*
|
2008-09-23 |
2008-10-29 |
Merck Sharp & Dohme |
New use
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US20120041066A1
(en)
*
|
2010-08-16 |
2012-02-16 |
Lombard Jay L |
Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
|
US20110237537A1
(en)
*
|
2009-05-29 |
2011-09-29 |
Lombard Jay L |
Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
|
US8355927B2
(en)
|
2010-11-05 |
2013-01-15 |
Genomind, Llc |
Neuropsychiatric test reports
|
US20120148509A1
(en)
*
|
2009-09-14 |
2012-06-14 |
Shiseido Company, Ltd. |
Composition for alleviating ultraviolet irradiation-induced damage
|
TWI544923B
(zh)
*
|
2009-12-29 |
2016-08-11 |
何應瑞 |
用於治療神經退化性疾病之醫藥組合物
|
EP2538939A1
(en)
*
|
2010-02-24 |
2013-01-02 |
Universität Zürich |
Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
|
US8258139B2
(en)
|
2010-11-08 |
2012-09-04 |
Dainippon Sumitomo Pharma Co., Ltd. |
Method of treatment for mental disorders
|
JP2014502958A
(ja)
*
|
2010-11-12 |
2014-02-06 |
プロメンテイス・フアーマシユーテイカルズ・インコーポレイテツド |
S−t−ブチル保護システインジペプチド類似体および関連化合物
|
US10583138B2
(en)
|
2012-07-12 |
2020-03-10 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
CA2826180C
(en)
*
|
2011-01-31 |
2020-09-01 |
Serotech, Llc |
Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
|
US9737531B2
(en)
*
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
PT2782566T
(pt)
|
2011-11-21 |
2021-03-03 |
The Inst For Ethnomedicine |
L-serina para uso no tratamento de distúrbios neurodegenerativos
|
US20130296430A1
(en)
*
|
2012-05-03 |
2013-11-07 |
Antonio Hardan |
Compositions and methods for treating autism and autism spectrum disorder
|
KR101499299B1
(ko)
*
|
2012-08-03 |
2015-03-09 |
연세대학교 산학협력단 |
Shank2 유전자가 결실된 자폐증 모델 형질전환마우스 및 그 용도
|
WO2014025905A1
(en)
*
|
2012-08-07 |
2014-02-13 |
Buck Institute For Research On Aging |
Multi-component formulation for improving neurological function
|
US9265458B2
(en)
|
2012-12-04 |
2016-02-23 |
Sync-Think, Inc. |
Application of smooth pursuit cognitive testing paradigms to clinical drug development
|
US9380976B2
(en)
|
2013-03-11 |
2016-07-05 |
Sync-Think, Inc. |
Optical neuroinformatics
|
AT514349B1
(de)
*
|
2013-06-12 |
2018-05-15 |
Red Bull Gmbh |
Alpha-alkylierte Aminosäuren (AAAAs)
|
WO2015031493A1
(en)
*
|
2013-08-27 |
2015-03-05 |
The Johns Hopkins University |
Amino acid treatment of seizures
|
US9675796B2
(en)
|
2013-11-10 |
2017-06-13 |
Brainsgate Ltd. |
Implant and delivery system for neural stimulator
|
US9877951B2
(en)
|
2015-02-12 |
2018-01-30 |
College Of William And Mary |
Method for treating dementia
|
WO2016132136A1
(en)
|
2015-02-18 |
2016-08-25 |
Aston University |
Diagnostic assay and treatment for preeclampsia
|
WO2016179252A1
(en)
|
2015-05-04 |
2016-11-10 |
Confluence Pharmaceuticals, Llc |
Sprinkle formulations of acamprosate
|
EP3093043B1
(en)
|
2015-05-13 |
2018-11-14 |
Brainsgate Ltd. |
Implant and delivery system for neural stimulator
|
US20180221315A1
(en)
*
|
2015-08-04 |
2018-08-09 |
Confluence Pharmaceuticals, Llc |
Combination therapy using acamprosate and d-cycloserine
|
US20170143681A1
(en)
|
2015-11-02 |
2017-05-25 |
Apkarian Technologies Llc |
Methods and compositions for treating pain
|
CN105476976B
(zh)
*
|
2015-12-22 |
2018-09-25 |
广州瑞尔医药科技有限公司 |
药物组合物及其制备方法和应用
|
JP6967532B2
(ja)
*
|
2016-05-25 |
2021-11-17 |
ナショナル ヘルス リサーチ インスティテューツNational Health Research Institutes |
付加的抗うつ剤組成物及びその使用方法
|
US9877942B1
(en)
*
|
2017-02-13 |
2018-01-30 |
Syneurx International (Taiwan) Corp. |
Co-crystals of substituted glycine and uses thereof
|
IL270654B2
(en)
|
2017-05-17 |
2024-07-01 |
Confluence Pharmaceuticals Llc |
Formulations of homotaurines and their salts
|
MX2019014114A
(es)
*
|
2017-05-25 |
2022-08-18 |
Glytech Llc |
Formulaciones para el tratamiento del trastorno de estres post-traumatico.
|
US10226442B2
(en)
*
|
2017-07-10 |
2019-03-12 |
Syneurx International (Taiwan) Corp. |
Lithium salts of N-substituted glycine compounds and uses thereof
|
MX2020005336A
(es)
|
2017-11-22 |
2020-08-13 |
Concert Pharmaceuticals Inc |
Analogos de d-serina deuterados y usos de los mismos.
|
KR101952443B1
(ko)
*
|
2018-08-23 |
2019-02-26 |
주식회사 아스트로젠 |
신규한 마그네슘세리네이트 화합물 및 이의 용도
|
EP4241774A1
(en)
*
|
2020-11-04 |
2023-09-13 |
Gliacelltech Inc. |
Composition for preventing or treating neuroinflammatory diseases, comprising chlorpromazine
|
WO2023171106A1
(ja)
*
|
2022-03-08 |
2023-09-14 |
ソシウム株式会社 |
Tdp-43の凝集の抑制剤、tdp-43が過剰発現している細胞の細胞死の抑制剤、及びtdp-43の凝集を伴う疾患の治療又は予防剤
|
WO2024204250A1
(ja)
*
|
2023-03-29 |
2024-10-03 |
株式会社明治 |
ドーパミン放出量増強剤、運動制御機能改善剤、運動学習機能改善剤及び活動意欲改善剤
|